Identification of Novel RORγt Inverse Agonist YW-089 as a Preclinical Candidate for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry · 12.11.2026
DOI: 10.1021/acs.jmedchem.6c01447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.11.2026. Verfasst von Yafei Huang und 12 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Retinoic acid receptor-related orphan receptor γt (RORγt) is a key regulator of IL-17-producing T helper 17 (Th17) cell differentiation and an attractive target for autoimmune diseases. Although RORγt inverse agonists have shown clinical promise, identifying candidates with both high potency and favorable drug-like properties remain challenging. We previously reported the carboxyl-containing biaryl urea compound 3i, which reduced psoriasis severity in mice but exhibited poor microsomal stability and suboptimal pharmacokinetics (38% oral bioavailability in mice). Herein, optimization of sulfone-containing biaryl ureas led to the discovery of compound 4 (YW-089), a potent and selective RORγt inverse agonist (RORγ FRET IC50 = 27 nM; mTh17 IC50 = 140 nM). YW-089 demonstrated markedly improved metabolic stability across species (t1/2 > 145 min), favorable pharmacokinetics in mice, rats, and dogs (oral bioavailability 66%, 65%, and 73%, respectively), and robust efficacy in imiquimod- and IL-23-induced psoriasis mouse models, supporting its further preclinical development for autoimmune diseases.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Huang, Y., Song, M., Sun, N., Yu, F., Chen, J., Guo, H., Tang, T., Yu, M., Zhao, Y., Zhu, C., Zhang, Z., Wang, Y., & Xie, Q. (2026). Identification of Novel RORγt Inverse Agonist YW-089 as a Preclinical Candidate for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01447
Vancouver
Huang Y, Song M, Sun N, Yu F, Chen J, Guo H, et al. Identification of Novel RORγt Inverse Agonist YW-089 as a Preclinical Candidate for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01447
BibTeX
@article{Huang2026,
author = {Huang, Yafei and Song, Meiqi and Sun, Nannan and Yu, Fazhi and Chen, Ji’an and Guo, Huimin and Tang, Ting and Yu, Mingcheng and Zhao, Yunpeng and Zhu, Chenyu and Zhang, Zhuojun and Wang, Yonghui and Xie, Qiong},
title = {Identification of Novel RORγt Inverse Agonist YW-089 as a Preclinical Candidate for the Treatment of Autoimmune Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01447}
}
EUVIMED